First Patient Dosed in Japanese Prostate Cancer Imaging Study
May 24, 2021 21:04 ET | Source: Telix Pharmaceuticals Limited Telix Pharmaceuticals Limited North Melbourne, AUSTRALIA
MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a clinical study in Japan using Telix’s investigational prostate cancer imaging product TLX591-CDx (Illuccix
®, Kit for the preparation of
68Ga-PSMA-11 injection). The study is an academic collaboration between Telix and Kanazawa University.
The study will enroll ten patients with advanced prostate cancer and is the first clinical evaluation of gallium-based PSMA imaging in Japan. The objective is to obtain safety data in a representative Japanese patient population, and to demonstrate that the targeting and biodistribution of TLX591-CDx in Japanese patients